Kelber O, Wittwer A, Lapke C, Kroll U, Weiser D, Okpanyi S N, Heilmann J
Scientific Department, Steigerwald Arzneimittelwerk GmbH, Havelstrasse 5, D-64295 Darmstadt, Germany.
Phytomedicine. 2006;13 Suppl 5:107-13. doi: 10.1016/j.phymed.2006.07.002. Epub 2006 Aug 22.
To correlate the pharmacological effects of the fixed herbal combination STW 5 (Iberogast) containing nine extract components with its confirmed clinical efficacy, ex vivo/in vitro absorption tests were performed. For the investigation, the everted gut sac technique and, in a pilot study, the Caco-2-cell model were used. The absorption rate of the extracts was determined by measuring characteristic marker substances of each of the individual extracts using HPLC or GC techniques. The results allow us to conclude that the investigated substances from STW 5 possess a good bioavailability, which is in accordance with the rapid onset of the therapeutic efficacy and explains its known pharmacological effects and clinical efficacy in terms of multiple drug action and multi-target therapy, respectively.
为了将含有九种提取物成分的固定草药组合STW 5（伊贝戈斯特）的药理作用与其已证实的临床疗效相关联，进行了体外/体内吸收试验。在研究中，采用了外翻肠囊技术，并在一项初步研究中使用了Caco-2细胞模型。通过使用HPLC或GC技术测量每种单独提取物的特征性标志物物质来确定提取物的吸收率。结果使我们能够得出结论，STW 5中所研究的物质具有良好的生物利用度，这与治疗效果的快速起效相一致，并分别从多药作用和多靶点治疗的角度解释了其已知的药理作用和临床疗效。
